SG11201900373WA - Bispecific proteins and methods for preparing same - Google Patents
Bispecific proteins and methods for preparing sameInfo
- Publication number
- SG11201900373WA SG11201900373WA SG11201900373WA SG11201900373WA SG11201900373WA SG 11201900373W A SG11201900373W A SG 11201900373WA SG 11201900373W A SG11201900373W A SG 11201900373WA SG 11201900373W A SG11201900373W A SG 11201900373WA SG 11201900373W A SG11201900373W A SG 11201900373WA
- Authority
- SG
- Singapore
- Prior art keywords
- domain
- chain
- methods
- bispecific proteins
- preparing same
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000006471 dimerization reaction Methods 0.000 abstract 1
- 238000005734 heterodimerization reaction Methods 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention relates to ab ispecific protein and amethod preparing the same, wherein mutation is introduced into heavy chains and/or light chains toenhance heterodimerization between ah eavy chain (CH3 domain or Fc) and ah eavy chain (CH3 domain 5 or Fc) and dimerization between ah eav yc hain (CH1 domain) and al ight chain, both targeting the same material, thereby constructing heterodimeric bispecific proteins of high purit y.A bispecific protein according to the present invention can find applications in av ariety of fields comprising cancer therapy, sing ling regulation, diagnosis, etc.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160091157 | 2016-07-19 | ||
| PCT/KR2017/007791 WO2018016881A1 (en) | 2016-07-19 | 2017-07-19 | Bispecific proteins and methods for preparing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900373WA true SG11201900373WA (en) | 2019-02-27 |
Family
ID=60992392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900373WA SG11201900373WA (en) | 2016-07-19 | 2017-07-19 | Bispecific proteins and methods for preparing same |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230075499A1 (en) |
| EP (1) | EP3489262A4 (en) |
| JP (2) | JP2019530641A (en) |
| KR (4) | KR102098919B1 (en) |
| CN (2) | CN117143247A (en) |
| AU (2) | AU2017298535B2 (en) |
| BR (1) | BR112019001138A2 (en) |
| CA (2) | CA3031082C (en) |
| IL (1) | IL264249B2 (en) |
| MX (1) | MX2019000925A (en) |
| MY (1) | MY200137A (en) |
| PH (1) | PH12019500138A1 (en) |
| RU (1) | RU2745648C2 (en) |
| SG (1) | SG11201900373WA (en) |
| WO (1) | WO2018016881A1 (en) |
| ZA (1) | ZA201900347B (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2644698B1 (en) | 2010-11-17 | 2018-01-03 | Chugai Seiyaku Kabushiki Kaisha | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| CA2853230C (en) | 2011-10-31 | 2021-11-23 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain |
| CA3071236A1 (en) * | 2017-09-29 | 2019-04-04 | Chugai Seiyaku Kabushiki Kaisha | Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient |
| US20220185887A1 (en) * | 2019-03-28 | 2022-06-16 | Ab Studio Inc. | Heteromultimeric proteins and methods of use thereof |
| BR112021020843A2 (en) * | 2019-04-25 | 2022-02-01 | Hoffmann La Roche | Set of heterodimeric precursor polypeptides, heterodimeric polypeptides, methods for generating a heterodimeric polypeptide and for identifying a multispecific heterodimeric polypeptide, multispecific heterodimeric polypeptide, first and second heterodimeric precursor polypeptides |
| US20230265134A1 (en) * | 2019-09-30 | 2023-08-24 | Adimab, Llc | Ch1 domain variants engineered for preferential light chain pairing and multispecific antibodies comprising the same |
| CN112646041B (en) * | 2019-10-12 | 2023-11-10 | 上海睿智化学研究有限公司 | Heterodimer comprising antibody CH3 domain and antibody and fusion protein comprising same |
| CN113121696A (en) * | 2019-12-31 | 2021-07-16 | 周易 | Bispecific antibody formed by Fab modification induction and preparation method and application thereof |
| KR20210095781A (en) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | A multi-specific antibody comprising a fusion construct consisting of a Fab and a bioactive effector moiety |
| GB202005879D0 (en) * | 2020-04-22 | 2020-06-03 | Petmedix Ltd | Heterodimeric proteins |
| IL298394A (en) * | 2020-05-21 | 2023-01-01 | Merus Nv | Methods and means for the production of ig-like molecules |
| JP2023534773A (en) | 2020-06-01 | 2023-08-10 | マストバイオ株式会社 | Bispecific antibody or antigen-binding fragment thereof, and method for producing the same |
| CN114437226A (en) * | 2020-11-05 | 2022-05-06 | 杭州菁因康生物科技有限公司 | Methods of making bispecific antibodies |
| EP4255934A1 (en) * | 2020-12-03 | 2023-10-11 | Zymeworks BC Inc. | Heterodimeric iga fc constructs and methods of use thereof |
| US20230116446A1 (en) * | 2021-09-21 | 2023-04-13 | Qilu Puget Sound Biotherapeutics Corporation | HETERODIMERIC Fc FOR MAKING FUSION PROTEINS AND BISPECIFIC ANTIBODIES |
| CN117586413A (en) * | 2022-08-09 | 2024-02-23 | 三生国健药业（上海）股份有限公司 | Heteromultimeric proteins and methods of making the same |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8309690B2 (en) * | 2005-07-01 | 2012-11-13 | Medimmune, Llc | Integrated approach for generating multidomain protein therapeutics |
| WO2009018411A1 (en) * | 2007-07-31 | 2009-02-05 | Regeneron Pharmaceuticals, Inc. | Human antibodies to human cd20 and method of using thereof |
| EP3239178A1 (en) * | 2007-12-14 | 2017-11-01 | Bristol-Myers Squibb Company | Binding molecules to the human ox40 receptor |
| SI2235064T1 (en) * | 2008-01-07 | 2016-04-29 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| CA2808154A1 (en) * | 2010-08-13 | 2012-02-16 | Medimmmune Limited | Monomeric polypeptides comprising variant fc regions and methods of use |
| CN103429620B (en) * | 2010-11-05 | 2018-03-06 | 酵活有限公司 | There is the antibody design of the stable heterodimeric of mutation in Fc domains |
| EP2686348B1 (en) | 2011-03-17 | 2015-12-30 | Ramot at Tel-Aviv University Ltd. | Bi- and monospecific, asymmetric antibodies and methods of generating the same |
| SG10201602371VA (en) * | 2011-03-25 | 2016-04-28 | Glenmark Pharmaceuticals Sa | Hetero-dimeric immunoglobulins |
| EA201100463A1 (en) * | 2011-04-05 | 2012-05-30 | Федеральное Государственное Бюджетное Учреждение "Научно-Исследовательский Институт Эпидемиологии И Микробиологии Имени Почетного Академика Н.Ф. Гамалеи" Министерства Здравоохранения И Социального Развития Российской Федерации | Recombinant PSEUDOADENOVIRUS NANOPARTICLES, PHARMACEUTICAL COMPOSITION FOR PREVENTION OR INFLUENZA THERAPY (OPTIONS), METHOD OF PREVENTION OR INFLUENZA THERAPY |
| JP2014514314A (en) * | 2011-04-20 | 2014-06-19 | ゲンマブ エー／エス | Bispecific antibodies against HER2 and CD3 |
| EP2543680A1 (en) * | 2011-07-07 | 2013-01-09 | Centre National de la Recherche Scientifique | Multispecific mutated antibody Fab fragments |
| AU2012328322A1 (en) * | 2011-10-27 | 2014-06-12 | Genmab A/S | Production of heterodimeric proteins |
| CA2853230C (en) * | 2011-10-31 | 2021-11-23 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain |
| KR101749316B1 (en) * | 2011-12-15 | 2017-06-21 | (주) 에이프로젠 | A Highly Potent Broad-Spectrum Neutralizing Monoclonal Antibody Derived From H1N1-Infected Patients and Method Of Treatment of Virus By Using Thereof |
| AU2013258834B2 (en) * | 2012-05-10 | 2017-09-07 | Zymeworks Bc Inc. | Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain |
| UY35148A (en) * | 2012-11-21 | 2014-05-30 | Amgen Inc | HETERODIMERIC IMMUNOGLOBULINS |
| WO2014084607A1 (en) * | 2012-11-27 | 2014-06-05 | 아주대학교산학협력단 | Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof |
| EP2943511B1 (en) * | 2013-01-14 | 2019-08-07 | Xencor, Inc. | Novel heterodimeric proteins |
| RU2015140915A (en) * | 2013-02-26 | 2017-04-03 | Роше Гликарт Аг | BSPECIFIC ANTI-BINDING MOLECULES ACTIVATING T-CELLS |
| EP3486255A3 (en) * | 2013-03-13 | 2019-11-13 | Ibentrus Inc. | Protein in which electrical interaction is introduced within hydrophobic interaction site and preparation method therefor |
| BR112016024780A2 (en) * | 2014-05-02 | 2017-10-10 | Momenta Pharmaceutical Inc | compositions and methods related to manipulated fc constructs |
| US9920118B2 (en) * | 2014-10-31 | 2018-03-20 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| WO2016086186A2 (en) * | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies including binding to cd8 |
| JP2017536830A (en) * | 2014-11-26 | 2017-12-14 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Heterodimeric antibodies that bind to CD3 and CD38 |
| IL252480B2 (en) * | 2014-11-26 | 2023-12-01 | Xencor Inc | Heterodimeric antibodies that bind cd3 and tumor antigens |
| US10982008B2 (en) * | 2014-12-05 | 2021-04-20 | Merck Patent Gmbh | Domain-exchanged antibody |
-
2017
- 2017-07-19 MX MX2019000925A patent/MX2019000925A/en unknown
- 2017-07-19 SG SG11201900373WA patent/SG11201900373WA/en unknown
- 2017-07-19 CA CA3031082A patent/CA3031082C/en active Active
- 2017-07-19 BR BR112019001138-2A patent/BR112019001138A2/en unknown
- 2017-07-19 WO PCT/KR2017/007791 patent/WO2018016881A1/en active Application Filing
- 2017-07-19 CN CN202311086544.XA patent/CN117143247A/en active Pending
- 2017-07-19 KR KR1020170091758A patent/KR102098919B1/en active IP Right Grant
- 2017-07-19 CN CN201780044935.1A patent/CN109476763B/en active Active
- 2017-07-19 US US16/317,987 patent/US20230075499A1/en active Pending
- 2017-07-19 CA CA3203613A patent/CA3203613A1/en active Pending
- 2017-07-19 MY MYPI2018002707A patent/MY200137A/en unknown
- 2017-07-19 JP JP2019502596A patent/JP2019530641A/en active Pending
- 2017-07-19 EP EP17831354.0A patent/EP3489262A4/en active Pending
- 2017-07-19 AU AU2017298535A patent/AU2017298535B2/en active Active
- 2017-07-19 RU RU2019103238A patent/RU2745648C2/en active
-
2019
- 2019-01-15 IL IL264249A patent/IL264249B2/en unknown
- 2019-01-17 ZA ZA2019/00347A patent/ZA201900347B/en unknown
- 2019-01-18 PH PH12019500138A patent/PH12019500138A1/en unknown
-
2020
- 2020-04-02 KR KR1020200040499A patent/KR102207260B1/en active IP Right Grant
- 2020-04-02 KR KR1020200040500A patent/KR102207261B1/en active IP Right Grant
- 2020-04-02 KR KR1020200040498A patent/KR20200042883A/en not_active Application Discontinuation
-
2021
- 2021-01-22 AU AU2021200412A patent/AU2021200412A1/en active Pending
- 2021-05-26 JP JP2021088111A patent/JP7335634B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900373WA (en) | Bispecific proteins and methods for preparing same | |
| AU2018366199A1 (en) | Bispecific and monospecific antibodies using novel anti-PD-1 sequences | |
| PH12017502019A1 (en) | Heterodimeric antibodies that bind cd3 and tumor antigens | |
| SA517381604B1 (en) | Novel heterodimeric antibodies | |
| ECSP17083788A (en) | ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF LIGHT CHAIN AMYLOIDOSIS AND OTHER CD38-POSITIVE HEMATOLOGIC MALIGNANT DISEASES | |
| PH12019500655A1 (en) | Heterodimeric immunoglobulin constructs and preparation methods thereof | |
| CL2017001090A1 (en) | Heterodimeric immunoglobulins of redirection of t-cells cd3 / cd38 and their production methods | |
| CL2017001660A1 (en) | Antibodies against the T-cell immunoreceptor with immunoglobulin domains and tyrosine-based immunoreceptor inhibitory motif (tigit) | |
| AU2018282038A1 (en) | Anti TRBC1 antigen binding domains | |
| EA201890028A1 (en) | HUMAN CD3 ANTIBODY | |
| EP3954713A3 (en) | Bispecific antibodies that bind to cd38 and cd3 | |
| MX2022006527A (en) | Modified antigen binding polypeptide constructs and uses thereof. | |
| MX2018008934A (en) | Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same. | |
| CL2019001352A1 (en) | Structural heterodimeric bispecific antibody of natural anti-pd-1 / anti-her2 antibody and method for preparing it. | |
| NZ597767A (en) | Antibodies to IL-6 and use thereof | |
| JOP20200177A1 (en) | Methods of treating cancers with antagonistic anti-pd-1 antibodies | |
| MX2019011585A (en) | Stable multispecific antibodies. | |
| WO2017117179A8 (en) | Bispecific antibodies having constant region mutations and uses therefor | |
| MX2020007880A (en) | Mica/b antibodies and methods of use. | |
| PH12021550232A1 (en) | Anti-mica/b antibodies that block mica/b shedding and methods of use | |
| BR112015027869A2 (en) | multistage process for olefin polymerization | |
| WO2020128870A3 (en) | Methods of producing heterodimeric antibodies | |
| CU20220019A7 (en) | NKG2D FUSION PROTEINS | |
| MX2016011228A (en) | Novel bispecific antibody binding to human tlr2 and human tlr4. | |
| MX2020006942A (en) | MODIFIED Cκ AND CH1 DOMAINS. |